Pieris Pharmaceuticals held its 2024 annual meeting where stockholders elected two directors, ratified the auditor, and approved executive compensation, while also addressing lawsuits related to a merger with Palvella Therapeutics and providing supplemental disclosures to avoid litigation costs.